Basilea reported strong preliminary revenues of CHF134m for FY2019E, marginally above the upper end of company guidance (CHF128m - CHF133m) and our own estimate (CHF133m). This figure includes a 39% YoY increase in revenues from Basilea's two marketed products, antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole), which totalled CHF114m. Key upcoming events for Basilea include (1) FY2019 financial results on the 18th of February and (2) top line results from the ongoing Phas ....
10 Jan 2020
Continued solid top-line growth for marketed products
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Continued solid top-line growth for marketed products
Basilea Pharmaceutica AG (0QNA:LON) | 0 0 0.0% | Mkt Cap: 605.3m
- Published:
10 Jan 2020 -
Author:
Chris Redhead -
Pages:
5
Basilea reported strong preliminary revenues of CHF134m for FY2019E, marginally above the upper end of company guidance (CHF128m - CHF133m) and our own estimate (CHF133m). This figure includes a 39% YoY increase in revenues from Basilea's two marketed products, antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole), which totalled CHF114m. Key upcoming events for Basilea include (1) FY2019 financial results on the 18th of February and (2) top line results from the ongoing Phas ....